Peripheral Artery Disease: Emerging Advances in Medical Therapy to Reduce Cardiovascular and Limb Risks

Peripheral artery disease (PAD) remains underdiagnosed and undertreated despite its association with high cardiovascular and limb event risks.
Multifaceted management strategies involving lifestyle modification, risk factor control, and advanced pharmacotherapy improve outcomes in PAD patients.
Dual pathway antithrombotic therapy with low-dose rivaroxaban plus aspirin significantly reduces both major adverse cardiovascular and limb events compared to single antiplatelet therapy.
Adjunctive lipid-lowering agents beyond statins, including ezetimibe, bempedoic acid, and PCSK9 inhibitors, help achieve LDL-C targets in PAD patients.
Novel antidiabetic medications, especially GLP-1 receptor agonists and SGLT2 inhibitors, provide cardiovascular and renal protection; GLP-1 RAs like semaglutide also exhibit potential limb event reduction.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Peripheral artery disease (PAD) remains underdiagnosed and undertreated despite its association with high cardiovascular and limb event risks.
Multifaceted management strategies involving lifestyle modification, risk factor control, and advanced pharmacotherapy improve outcomes in PAD patients.
Dual pathway antithrombotic therapy with low-dose rivaroxaban plus aspirin significantly reduces both major adverse cardiovascular and limb events compared to single antiplatelet therapy.
Adjunctive lipid-lowering agents beyond statins, including ezetimibe, bempedoic acid, and PCSK9 inhibitors, help achieve LDL-C targets in PAD patients.
Novel antidiabetic medications, especially GLP-1 receptor agonists and SGLT2 inhibitors, provide cardiovascular and renal protection; GLP-1 RAs like semaglutide also exhibit potential limb event reduction.

Sign in free to continue reading